FDA grants swift review to Lynparza in first-line prostate cancer
pharmaphorum
AUGUST 16, 2022
AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marketing application is approved by the FDA. The post FDA grants swift review to Lynparza in first-line prostate cancer appeared first on.
Let's personalize your content